NanoPin Technologies Inc. focuses on advancing infectious disease diagnostics through innovative platforms that deliver rapid and accurate results from patient samples. Their technology is particularly adept at detecting low levels of active disease biomarkers, distinguishing between latent and active infections, which is crucial for diseases like tuberculosis (TB) and HIV. The company has developed proprietary diagnostic assays that can effectively identify TB in diverse patient populations, including children, infants, and immunocompromised individuals. This versatility is essential in addressing the global burden of infectious diseases, as it allows for tailored diagnostics that meet the needs of various demographics.

The diagnostic platform developed by NanoPin is designed to be adaptable for future infectious disease threats, making it a valuable tool in the ongoing battle against epidemics. Their commitment to enhancing their intellectual property and collaborating with partners, such as Thermo Fisher Scientific, underscores their dedication to improving patient care and public health outcomes. By focusing on diseases with significant mortality rates, such as TB and HIV, NanoPin aims to provide healthcare providers with advanced tools necessary for effective disease management and response to emerging health crises.

United States

Developing a technology platform that includes proprietary antibody-conjugated nanoparticles that are specifically adapted to antigen peptides that are only present in the bloodstream when the targeted disease is active.

NanoPin

Company Details